BLCO
Bausch + Lomb Corp
$
15.380
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.410
Open
15.200
VWAP
15.21
Vol
37.90K
Mkt Cap
5.40B
Low
15.200
Amount
576.50K
EV/EBITDA(TTM)
19.21
Total Shares
351.48M
EV
10.16B
EV/OCF(TTM)
54.62
P/S(TTM)
1.10
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
1.28B
+6.69%
0.164
-3.33%
1.39B
+8.47%
0.353
+41.24%
1.20B
+5.87%
0.109
-255.86%
Estimates Revision
The market is revising Upward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by 1.05% over the past three months. During the same period, the stock price has changed by 28.17%.
Revenue Estimates for FY2025
Revise Upward
+1.05%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+10.49%
In Past 3 Month
Stock Price
Go Up
+28.17%
In Past 3 Month
11 Analyst Rating
-4.75% Downside
Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 14.65 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
1 Sell
Hold
-4.75% Downside
Current: 15.380
Low
12.00
Averages
14.65
High
17.00
-4.75% Downside
Current: 15.380
Low
12.00
Averages
14.65
High
17.00
Citi
Neutral
maintain
$13 -> $15
2025-07-09
Reason
Citi
Price Target
$13 -> $15
2025-07-09
maintain
Neutral
Reason
Citi raised the firm's price target on Bausch + Lomb to $15 from $13 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Barclays
Matt Miksic
Equal Weight
downgrade
$19 -> $16
2025-06-09
Reason
Barclays
Matt Miksic
Price Target
$19 -> $16
2025-06-09
downgrade
Equal Weight
Reason
Barclays analyst Matt Miksic lowered the firm's price target on Bausch + Lomb to $16 from $19 and keeps an Equal Weight rating on the shares. The company confirmed at an investor conference that it will be able to offset its 25c tariff headwind, the analyst tells investors in a research note. The firm cut the price target but expects Bausch + Lomb to potentially trade higher in the near-term on this update.
RBC Capital
Douglas Miehm
Buy
Maintains
$18 → $17
2025-04-04
Reason
RBC Capital
Douglas Miehm
Price Target
$18 → $17
2025-04-04
Maintains
Buy
Reason
After Bausch + Lomb announced a voluntary recall of its enVista intraocular lenses, RBC Capital says talks with management indicated that it remains too early to determine the financial impact. However, the firm's view is the event may lead to a charge in Q1 and a negative impact on surgery group operations until the products are returned to the market, based on similar recalls that have occurred at other companies. The current stock price decline of 6% reflects a market cap erosion of about $330M, which is higher than the $184M enterprise value that RBC ascribes to the entire surgical segment, notes the analyst, who views the stock price reaction as "likely overdone." RBC has an Outperform rating and $18 price target on B+L shares.
Stifel
Tom Stephan
Hold
Maintains
$17 → $15
2025-04-03
Reason
Stifel
Tom Stephan
Price Target
$17 → $15
2025-04-03
Maintains
Hold
Reason
Stifel lowered the firm's price target on Bausch + Lomb to $15 from $17 and keeps a Hold rating on the shares. Following last week's intraocular lense recall, the firm surveyed 54 ophthalmologists to assess the impact on B+L and broader market implications, telling investors that the survey findings were "less negative than anticipated" as a greater-than-expected proportion of doctors plan to resume using the recalled IOLs once available.
Wells Fargo
Larry Biegelsen
Buy
to
Hold
Downgrades
$24 → $15
2025-03-28
Reason
Wells Fargo
Larry Biegelsen
Price Target
$24 → $15
2025-03-28
Downgrades
Buy
to
Hold
Reason
Wells Fargo downgraded Bausch + Lomb to Equal Weight from Overweight with a price target of $15, down from $24.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$23 → $20
2025-02-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$23 → $20
2025-02-21
Maintains
Strong Buy
Reason
BofA lowered the firm's price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb's separation from Bausch Health (BHC), the analyst added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 18.86, compared to its 5-year average forward P/E of 21.35. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
21.35
Current PE
18.86
Overvalued PE
25.50
Undervalued PE
17.19
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
10.61
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.39
Undervalued EV/EBITDA
9.83
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.28
Current PS
0.00
Overvalued PS
1.50
Undervalued PS
1.06
Financials
Annual
Quarterly
FY2025Q2
YoY :
+5.10%
1.28B
Total Revenue
FY2025Q2
YoY :
-72.97%
10.00M
Operating Profit
FY2025Q2
YoY :
-60.81%
-58.00M
Net Income after Tax
FY2025Q2
YoY :
-58.14%
-0.18
EPS - Diluted
FY2025Q2
YoY :
-5.26%
-54.00M
Free Cash Flow
FY2025Q2
YoY :
-0.94%
53.68
Gross Profit Margin - %
FY2025Q2
YoY :
+13.09%
-3.37
FCF Margin - %
FY2025Q2
YoY :
-62.70%
-4.54
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
268.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.2M
Volume
1
6-9
Months
2.6M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.0M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
268.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BLCO News & Events
Events Timeline
2025-09-11 (ET)
2025-09-11
07:06:27
Bausch + Lomb Releases Results from enVista Envy Clinical Trials
2025-09-09 (ET)
2025-09-09
08:07:12
Bausch + Lomb Releases Findings from Xiidra 5% Research Study
2025-08-18 (ET)
2025-08-18
17:03:07
Bausch + Lomb reveals resignation of Brett Icahn and Gary Hu from the board
Sign Up For More Events
Sign Up For More Events
News
9.0
09-11NewsfilterBausch + Lomb Reveals Results of Pivotal U.S. Clinical Trial for enVista Envy™ Full Range of Vision Intraocular Lens
4.0
08-25NASDAQ.COMBLCO Surpasses Average Analyst Expectations
1.0
08-14Yahoo FinanceBausch + Lomb to Participate in Upcoming Investor Conferences
Sign Up For More News
People Also Watch
TRNO
Terreno Realty Corp
58.920
USD
+0.17%
NOV
Nov Inc
13.440
USD
+6.67%
HOMB
Home BancShares Inc
29.220
USD
+0.93%
COLD
Americold Realty Trust Inc
12.610
USD
-1.64%
LEGN
Legend Biotech Corp
34.130
USD
+0.15%
HIMS
Hims & Hers Health Inc
55.882
USD
-3.15%
ASTS
AST SpaceMobile Inc
54.350
USD
+11.26%
MMSI
Merit Medical Systems Inc
83.820
USD
+0.28%
HMY
Harmony Gold Mining Company Ltd
18.365
USD
+4.29%
MAT
Mattel Inc
17.190
USD
+0.64%
FAQ
What is Bausch + Lomb Corp (BLCO) stock price today?
The current price of BLCO is 15.38 USD — it has increased 0.85 % in the last trading day.
What is Bausch + Lomb Corp (BLCO)'s business?
What is the price predicton of BLCO Stock?
What is Bausch + Lomb Corp (BLCO)'s revenue for the last quarter?
What is Bausch + Lomb Corp (BLCO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bausch + Lomb Corp (BLCO)'s fundamentals?
How many employees does Bausch + Lomb Corp (BLCO). have?